Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

David R. Fogelman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4063-189X; OpenAlex author ID A5004999918. Sources: ClinicalTrials.gov.

Their work

Papers
46 (first author 0, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
128
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper, 1 trial · 2014: 4 papers · 2015: 3 papers · 2016: 3 papers · 2017: 5 papers · 2018: 5 papers · 2019: 9 papers · 2020: 8 papers, 1 trial · 2021: 3 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 46

  1. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  2. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Pha… Co-author DOI 10.1001/jamaoncol.2021.0006↗
  3. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  4. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  5. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  6. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  7. A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. Last author DOI 10.1016/j.jpainsymman.2020.01.007↗
  8. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
  9. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  10. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-0224↗
  11. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  12. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  13. Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/cam4.2157↗
  14. Physical activity and exercise during preoperative pancreatic cancer treatment. Co-author DOI 10.1007/s00520-018-4493-6↗
  15. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  16. Dual-Energy X-Ray Absorptiometry Compared to Computed Tomography for Visceral Adiposity Assessment Among Gastrointestinal and Pancreatic Cancer Survivors. Co-author DOI 10.1038/s41598-019-48027-1↗
  17. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIR… Co-author DOI 10.1097/mpa.0000000000001345↗
  18. Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. Co-author DOI 10.1123/jpah.2019-0027↗
  19. Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life. Co-author DOI 10.1177/1534735419894061↗
  20. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  21. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  22. Medical oncology and pancreatic cancer: what the radiologist needs to know. Co-author DOI 10.1007/s00261-017-1432-9↗
  23. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. Co-author DOI 10.1007/s11605-017-3618-4↗
  24. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
  25. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-18-0014↗
  26. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic… Co-author DOI 10.1186/s13045-018-0616-2↗
  27. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2017.2227↗
  28. Home-based exercise during preoperative therapy for pancreatic cancer. Co-author DOI 10.1007/s00423-017-1599-0↗
  29. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Co-author DOI 10.1007/s00520-016-3553-z↗
  30. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  31. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Co-author DOI 10.18632/oncotarget.19897↗
  32. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗
  33. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  34. Poster 68 Feasibility of a Prehabilitation Program for Patients with Potentially Resectable Pancreatic Cancer: Pilot Study. Co-author DOI 10.1016/j.pmrj.2016.07.111↗
  35. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2788-6↗
  36. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-014-4285-2↗
  37. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Co-author DOI 10.1245/s10434-015-4854-z↗
  38. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective tria… Co-author DOI 10.1002/cncr.28648↗
  39. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Co-author DOI 10.1007/s13539-014-0145-y↗
  40. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. Co-author DOI 10.1016/j.jamcollsurg.2014.02.023↗
  41. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-con… Co-author DOI 10.1097/mpa.0000000000000095↗
  42. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Last author DOI 10.1007/s10637-013-9967-2↗
  43. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Last author DOI 10.1007/s00280-011-1705-x↗
  44. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therap… Co-author DOI 10.1245/s10434-011-2211-4↗
  45. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Co-author DOI 10.1007/s00280-011-1601-4↗
  46. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Co-author PMID 21508395↗

Trials 2

  1. Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer Principal investigator NCT04058964↗
  2. Minocycline Study in Pancreatic Cancer Patients Principal investigator NCT01693523↗

Closest collaborators

The 25 strongest of 128 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert A. Wolff · 29 shared papers, 2011–2026 · strength 2.05
  2. Matthew H. G. Katz · 28 shared papers, 2012–2021 · strength 1.90
  3. Gauri Rajani Varadhachary · 27 shared papers, 2011–2021 · strength 1.88
  4. Milind M. Javle · 23 shared papers, 2011–2021 · strength 1.57
  5. Michael James Overman · 16 shared papers, 2013–2026 · strength 1.33
  6. Jeffrey E. Lee · 20 shared papers, 2012–2021 · strength 1.32
  7. Shubham Pant · 10 shared papers, 2014–2026 · strength 1.03
  8. Laura R. Prakash · 14 shared papers, 2016–2021 · strength 1.03
  9. Ching-Wei David Tzeng · 13 shared papers, 2012–2021 · strength 0.99
  10. Rachna T. Shroff · 14 shared papers, 2014–2020 · strength 0.90
  11. Eugene Jon Koay · 12 shared papers, 2016–2021 · strength 0.87
  12. Michael P. Kim · 11 shared papers, 2016–2021 · strength 0.84
  13. Jason B. Fleming · 14 shared papers, 2012–2019 · strength 0.76
  14. Anirban Maitra · 9 shared papers, 2016–2026 · strength 0.70
  15. Florencia M. McAllister · 6 shared papers, 2018–2026 · strength 0.69
  16. Nathan H. Parker · 9 shared papers, 2014–2019 · strength 0.61
  17. Joseph M. Herman · 7 shared papers, 2017–2021 · strength 0.59
  18. An Ngo‐Huang · 8 shared papers, 2015–2019 · strength 0.57
  19. Maria Q. B. Petzel · 8 shared papers, 2015–2019 · strength 0.57
  20. Huamin Wang · 8 shared papers, 2015–2021 · strength 0.50
  21. Eric Peter Tamm · 6 shared papers, 2012–2020 · strength 0.38
  22. Giampaolo Perri · 4 shared papers, 2020–2021 · strength 0.38
  23. Naruhiko Ikoma · 4 shared papers, 2020–2021 · strength 0.38
  24. Priya Bhosale · 5 shared papers, 2017–2021 · strength 0.38
  25. Karen M. Basen-Engquist · 4 shared papers, 2019 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.